In addition, relatively low O-GlcNAcylation levels have been found in patients with Alzheimer’s disease (AD), and genetic or pharmacological downregulation of O-GlcNAcylation has led to increased neuron loss, Aβ aggregation, tau hyperphosphorylation, and even learning and memory deficits in mice35,38,39. This evidence concerns the gene MAPT and early-onset autosomal dominant Alzheimer disease.